Medullary Thyroid Carcinoma Associated with Hyperthyroidism: A Case Report and Review of the Literature

Habra, Mouhammed Amir; Hijazi, Rabih; Verstovsek, Gordana; Marcelli, Marco

doi:10.1089/105072504774193249

Cited by 15 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Le plus fréquent est le carcinome papillaire de la thyroïde. L'association avec le carcinome anaplasique et médullaire est exceptionnelle [2, 3], cela est dû aussi à la faible incidence de ces cancers en général.…”

Section: Discussionunclassified

Association hyperthyroïdie et cancers différenciés de la thyroïde

Haraj¹,

Ahandar²,

Aziz³

et al. 2016

Pan Afr Med J

View full text Add to dashboard Cite

La présence d'une hyperthyroïdie n'est plus une assurance contre la survenue d'un cancer thyroïdien. L'association des deux n'est pas rare. Il s'agit d'une étude rétrospective de 355 dossiers de patients suivis pour cancer différenciés de la thyroïde au service d'endocrinologie du CHU Ibn Rochd entre 1986 et 2014, on retrouve douze patients suivis pour hyperthyroïdie chez qui une association fortuite avec un cancer différenciés de la thyroïde a été découverte sur l'examen anatomopathologique, soit une prévalence de 3.38%. L’âge moyen à la découverte est de 44,8 ans, avec une nette prédominance féminine (8/12). Huit patients avaient un nodule toxique, 3 goitres basedowifiés et un cas de maladie de basedow. Tous ont bénéficié d'une thyroïdectomie totale. Il s'agissait de carcinome papillaire chez tous les patients. Le microcarcinome était le plus prédominant (6 patients). Un carcinome insulaire était retrouvé chez une patiente, avec présence de métastases rachidiennes et rétro orbitaire. Un traitement par l'iode radioactif a été indiqué chez cinq patients. Le diagnostic de l'hyperthyroïdie n’élimine pas la possibilité d'un cancer thyroïdien associé. La malignité doit toujours être gardée à l'esprit et de ce fait proposer une démarche diagnostique comparable à celle établie pour tout nodule thyroïdien.

show abstract

Section: Discussionunclassified

Association hyperthyroïdie et cancers différenciés de la thyroïde

Haraj¹,

Ahandar²,

Aziz³

et al. 2016

Pan Afr Med J

View full text Add to dashboard Cite

show abstract

“…The prevalence of concomitant thyroid cancer occurring in patients with Graves' disease reach up to 17% (Weber et al 2006). Although PTC is the most frequently reported histologic type happened in Graves' disease, MTC with concomitant Graves' disease has also been reported (Habra et al 2004), and other clinicopathological characteristics and survival features of thyroid cancer associated with Graves' disease or euthyroidism remain controversial among studies (Pellegriti et al 1998, Yano et al 2007, Pazaitou-Panayiotou et al 2012. MLS, defined as concomitant occurrence of autonomously functioning thyroid nodule (AFTN) and Graves' disease (Marine & Lenhart 1911), has the possibility of coexisting DTC as well (Scherer et al 2013).…”

Section: Graves' Disease With Concomitant Thyroid Cancermentioning

confidence: 99%

“…MTC sometimes associates with multiple endocrine neoplasia (MEN) syndromes, however, none of the reported cases of Graves' disease associated with MTC was finally diagnosed as MEN (Habra et al 2004), and the mechanism of Graves' disease associated with MTC is still unclear.…”

Section: Mechanismmentioning

confidence: 99%

“…For Graves' disease with concomitant MTC, total thyroidectomy under biochemical euthyroidism achieved by administration of ATDs and beta-blockers is appropriate (Habra et al 2004). If the evidence of extrathyroidal tumor extension and metastases existed, adjuvant therapy such as radiation therapy or molecular targeted therapy would be needed (Brierley et al 1996, Solomon & Rischin 2012.…”

Section: Treatmentmentioning

confidence: 99%

See 1 more Smart Citation

Thyrotoxicosis with concomitant thyroid cancer

Cheng

Jin

et al. 2019

Endocrine-Related Cancer

View full text Add to dashboard Cite

Thyrotoxicosis with concomitant thyroid cancer is rare and poorly recognized, which may result in delayed diagnosis, inappropriate treatment and even poor prognosis. To provide a comprehensive guidance for clinicians, the etiology, pathogenesis, diagnosis and treatment of this challenging setting were systematically reviewed. According to literatures available, the etiologies of thyrotoxicosis with concomitant thyroid cancer were categorized into Graves’ disease with concurrent differentiated thyroid cancer (DTC) or medullary thyroid cancer, Marine–Lenhart Syndrome with coexisting DTC, Plummer’s disease with concomitant DTC, amiodarone-induced thyrotoxicosis with concomitant DTC, central hyperthyroidism with coexisting DTC, hyperfunctioning metastases of DTC and others. The underlying causal mechanisms linking thyrotoxicosis and thyroid cancer were elucidated. Medical history, biochemical assessments, radioiodine uptake, anatomic and metabolic imaging and ultrasonography-guided fine-needle aspiration combined with pathological examinations were found to be critical for precise diagnosis. Surgery remains a mainstay in both tumor elimination and control of thyrotoxicosis, while anti-thyroid drugs, beta-blockers, 131I, glucocorticoids, plasmapheresis, somatostatin analogs, dopamine agonists, radiation therapy, chemotherapy and tyrosine kinase inhibitors should also be appropriately utilized as needed.

show abstract

“…Tiroid kanserlerinin tüm histolojik tipleri hipertiroidizme eşlik edebilmektedir. Ancak sıklıkla papiller tiroid kanserleri ardından folliküler ve nadiren de anaplastik ve medüller tiroid kanserlerinin eşlik edebileceği rapor edilmiştir (8)(9)(10)(11)(12). Çalışmamızdaki oranlarda literatür ile uyumlu bulunmuştur.…”

Section: Gereç Ve Yöntemunclassified

Evaluation of thyroid cancer prevalence in patients with graves disease

et al. 2019

View full text Add to dashboard Cite

Amaç: Graves hastalığı ve tiroid kanserleri sık görülen hastalıklar olmasına rağmen her iki hastalığın birlikteliği nadir bir durum olarak karşımıza çıkmaktadır. Bu durumun nadir olmasında hipertiroidinin, tiroid kanserine karşı koruyucu bir etkisinin olduğunu düşündürmektedir. Çalışmamızda graves hastalığı nedeni ile total tiroidektomi uyguladığımız hastalardaki tiroid kanser sıklığını belirlemeyi amaçladık. Gereç ve Yöntem:2009-2018 yılları arasında graves hastalığı nedeni ile total tiroidektomi yapılan 210 hastanın dosyası geriye dönük olarak incelendi ve patoloji sonucunda tiroid kanseri tanısı alan 38 hasta demografik ve klinik özellikleri açısından değerlendirildi. Bulgular: Hastaların 25'i (%65,8) kadın, 13'ü (%34,2) erkek ve ortalama yaşları 40 (17-68) idi. Ultrasonografik incelemede tüm hastaların (43/210) %20' de tiroid bezinde nodül varken, patoloji sonucunda karsinom tespit edilen hastaların (22/38) %57'sinde nodül mevcuttu. Tiroidektomi yapılan hastaların patolojik incelemelerinde 38 (%18) hastada tiroid kanseri mevcuttu. Tiroidektomi sonrası 1 hastaya boyun diseksiyonu uygulandı. On iki hastaya radyoaktif iyot tedavisi uygulandı. Ortalama takip süresi 30 (3-108) ay idi. Takiplerde 2 (%5,2) hastada 12. ve 18. aylarda tiroidektomi lojunda papiller kanser nüksü görüldü. Her iki hastaya da RAİ tedavisi uygulandı. Takiplerde nüks izlenmedi. Sonuç: Graves hastalığı ve tiroid kanser birlikteliği nadir olsa da özellikle graves hastalığı nedeni ile takip edilen ve yapılan ultrasonografide nodül bulunan hastalarda mutlaka ince iğne aspirasyon biyopsisi yapılmalıdır. Tiroid dokusunda nodül içeren graves hastalarında cerrahi tedavi seçeneği daha ön planda düşünülmelidir.Anahtar Sözcükler: Graves hastalığı, tiroid kanseri, nodül. ÖzAim: Although Graves' disease and thyroid cancer are commonly occurring diseases, simultaneous occurence is rare. Hyperthyroidism is believed to be protective against thyroid cancer hence the rare simultaneous occurrence. In our study we intend to evaluate thyroid cancer prevalence in patients operated for Graves' disease in our center. Materials and Methods:Files of 210 patients who underwent total thyroidectomy for Graves' disease between 2009-2018 were retrospectively reviewed. Demographic and clinical features of 38 patients with thyroid cancer diagnosis in the pathology report were evaluated. Results:In our study 25 (65.8%) of the patients were women, 13 (34.2%) were men and the average age was 40 . In ultrasonographic imaging 20% (43/210) of the patients had thyroid nodules, while 57% (22/38) of patients with confirmed carcinoma in the pathologic evaluation had thyroid nodules. Functional neck dissection was performed on1 patient secondary to thyroidectomy. 12 of the patient received radioactive iodine treatment. Our average followup period was 30 (3-108) months. During the follow-up 2 (5.2%) patients had recurrence of papillary cancer in the thryoidectomy area at 12th and 18th months. Both patients received RAI treatment. There was no subsequent recurrence in the follow-up of b...

show abstract

Medullary Thyroid Carcinoma Associated with Hyperthyroidism: A Case Report and Review of the Literature

Cited by 15 publications

References 38 publications

Association hyperthyroïdie et cancers différenciés de la thyroïde

Association hyperthyroïdie et cancers différenciés de la thyroïde

Thyrotoxicosis with concomitant thyroid cancer

Evaluation of thyroid cancer prevalence in patients with graves disease

Contact Info

Product

Resources

About